Article

OSI collaborates on drug's sustained release

Fort Collins, CO?PR Pharmaceuticals (PRP) will work with OSI Pharmaceuticals to develop a sustained-release formulation of pegaptanib sodium injection (Macugen) using its proprietary ProPhase encapsulation technology.

Fort Collins, CO-PR Pharmaceuticals (PRP) will work with OSI Pharmaceuticals to develop a sustained-release formulation of pegaptanib sodium injection (Macugen) using its proprietary ProPhase encapsulation technology.

The deal gives OSI an exclusive license to use the encapsulation technology with the drug in the treatment of eye diseases. PRP will develop the formulations and manufacture the test product for non-clinical and clinical trials.

OSI's eye disease unit, Eyetech Pharmaceuticals, will be responsible for clinical development activities and may manufacture and commercialize any resulting product.

Pegaptanib sodium injection was approved Feb. 2 for sale in the Europe-and previously was marketed in the United States, Canada, and five other countries-for the treatment of neovascular age-related macular degeneration. Pfizer Inc. has exclusive rights to market the drug outside the United States under a royalty-bearing license agreement.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.